Colorectal and Peritoneal Oncology Annual Service Report 2021 - 2022

Service Report 2022 Colorectal and Peritoneal Oncology Centre – The Christie NHS Foundation Trust

• “ Ultrasound guided day case percutaneous wide bore aspiration of Pseudomyxoma peritonei ” presented by Dr Philip Borg (Consultant Interventional Radiologist, The Christie Hospital NHS Foundation Trust) & “ The BROAC-TRIAL: a supportive role for Bromelain and Acetylcysteine in advanced PMP ” presented by Dr Lidia Rodríguez Ortiz (University Hospital Reina Sofia, Spain) and Dr Arjona Sanchez (University Hospital Reina Sofia, Spain) – Dec 2022 • “ Adenocarcinoma of the appendix - Outcomes from CRS HIPEC at The Christie ” presented by Dr Strach (University of Manchester) & “ CRUK Accelerator project (Pseudomyxoma peritonei: building a European multicentric cohort to accelerate new therapeutic perspectives) update ” presented by Dr Barriuso – April 2022 • “ The T cell receptor repertoire of tumour infiltrating T cells: an introduction " presented by Dr Sara Valpione & “ The quantification of T cell infiltration and clonality identifies distinct prognostic groups in colorectal cancer ” presen ted by Dr Luca G. Campana - September 2021 • “ The Role of JAK/STAT3 cascade in colorectal cancer " presented by Professor Joanne Edwards (University of Glasgow) & “ Is the microenvironment the key to stratify patients with CRPMs? " presented by Dr Jorge Barriuso - May 2021

• ‘ Histopathology and Classification of Appendiceal Tumours ’ Dr B Chakrabarty, March 2021

• Prodige 7 trial paper & NIHR EVidencE Review of PEritoneal Tumour (EVERPET) project Mr Aziz , Prof Kurunchi - February 2021

• “ Proteomics: Potential for advanced biomarker discovery ” . Dr. Richard Unwin (Deputy Director, Stoller Biomarker Discovery Centre) & Professor Paul Townsend (co-Director of Manchester Centre for Cellular Metabolism), University of Manchester. February 2020

5 RESEARCH

We continue to expand our research portfolio. Over the past year we have established The Christie Colorectal and Peritoneal Oncology Centre (CPOC) Academy and Lab, at theManchester Cancer Research Centre. Despite the challenges of the pandemic, we have grown our collective research team which now comprises of; 5 PhD students, an academic clinical lecturer (50% clinical/50% academic), an ESMO fellow, 2 postdoctoral research fellows, and a research manager. This team is funded through the grants listed in section 5.5. Our key research themes include:

Biomarker research

•

Technology and Innovation

•

• Clinical outcomes and treatment effects

5.1 Biomarker Research

5.1.1 Cancer Research UK Accelerator Award: Pseudomyxoma peritonei: building a European multicentric cohort to accelerate new therapeutic perspectives – We are one of three European groups (including Italy and Spain) that have been awarded this prestigious award to accelerate the collection of a

16